
LCTX Stock Forecast & Price Target
LCTX Analyst Ratings
Bulls say
Lineage Cell Therapeutics Inc. is advancing its innovative ReSonance program, which focuses on developing auditory neuronal cell transplants to enhance cochlear implant outcomes for patients with severe-to-profound hearing loss, highlighting its progress in addressing significant unmet medical needs. The company has successfully reached key preclinical stages of this program with minimal incremental investment, showcasing its efficient use of resources and strategic development. Additionally, a financial commitment of up to $12 million from William Demant Invest provides crucial funding that supports the ongoing development of Lineage’s therapeutic candidates and strengthens its financial position.
Bears say
Lineage Cell Therapeutics Inc has faced challenges due to the clinical uncertainties associated with its product pipeline, particularly the reliance on multiple unproven therapies, which increases the risk profile for investors. Financially, the company has reported limited revenue generation, resulting in a reliance on external financing to support ongoing research and development efforts. Additionally, the potential for lengthy regulatory approval processes further compounds the risk of delayed commercialization and revenue realization for its key product candidates.
This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LCTX Analyst Forecast & Price Prediction
Start investing in LCTX
Order type
Buy in
Order amount
Est. shares
0 shares